Detalhe da pesquisa
1.
Fenfluramine hydrochloride for the treatment of seizures in Dravet syndrome: a randomised, double-blind, placebo-controlled trial.
Lancet
; 394(10216): 2243-2254, 2019 12 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-31862249
2.
Development and content validation of a preliminary core set of patient- and caregiver-relevant outcomes for inclusion in a potential composite endpoint for Dravet Syndrome.
Epilepsy Behav
; 78: 232-242, 2018 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29108913
3.
The patient clinical journey and socioeconomic impact of osteogenesis imperfecta: a systematic scoping review.
Orphanet J Rare Dis
; 18(1): 34, 2023 Feb 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-36814274
4.
Fenfluramine for Treatment-Resistant Seizures in Patients With Dravet Syndrome Receiving Stiripentol-Inclusive Regimens: A Randomized Clinical Trial.
JAMA Neurol
; 77(3): 300-308, 2020 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31790543
5.
Determinación de la epidemiología, el flujo de pacientes y el tratamiento del síndrome de Dravet en España / Ascertaining the epidemiology, patient flow and disease management for Dravet syndrome in Spain
Rev. neurol. (Ed. impr.)
; 68(2): 75-81, 16 ene., 2019. graf
Artigo
em Espanhol
| IBECS (Espanha) | ID: ibc-177236
6.
Treatment outcomes in the STAR study: a subanalysis of solifenacin 5 mg and tolterodine ER 4 mg.
Eur Urol
; 52(4): 1195-203, 2007 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-17574730